Results 51 to 60 of about 1,580 (184)

Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic‐Cardiodynamic Modeling to Support Safety and Efficacy

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT In the phase 3 study SEQUOIA‐HCM (NCT05186818), aficamten, a next‐in‐class cardiac myosin inhibitor, was safe and efficacious in participants with obstructive hypertrophic cardiomyopathy (oHCM). Using pharmacokinetics/pharmacodynamics (PKPD) modeling, we quantified the relationship between aficamten exposure and cardiodynamic measures of ...
Justin D. Lutz, Russ Wada, Daniel L. Jacoby, Stephen B. Heitner, Stuart Kupfer, Polina German   +5 more
wiley   +1 more source

Managing drug–drug interactions with mavacamten : A focus on combined use of antiarrhythmic drugs and anticoagulants [PDF]

Mavacamten is a selective, allosteric, and reversible cardiac myosin inhibitor, representing the first disease-specific treatment for obstructive hypertrophic cardiomyopathy (HCM) that targets the core pathophysiological mechanism of this condition ...
Molinari, Lorenzo V., Mansour, Davide,, Renda, Giulia, Mansour, Davide, Ricci, Fabrizio, Ricci, Fabrizio,, Luzum, Jasmine A., Khanji, Mohammed Y., Olivotto, Iacopo,, Chahal, Anwar A., Molinari, Lorenzo V.,, Renda, Giulia,, Gallina, Sabina,, Vagnarelli, Fabio, Galanti, Kristian, Luzum, Jasmine A.,, Chahal, Anwar A.,, Galanti, Kristian,, Vagnarelli, Fabio,, Gallina, Sabina, Owens, Anjali, Khanji, Mohammed Y.,, Lund University., Owens, Anjali,, Olivotto, Iacopo   +24 more
core   +1 more source

Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations

, 2020
Thin filament hypertrophic cardiomyopathy (HCM) mutations increase myofilament Ca2+- sensitivity and alter Ca2+ handling and buffering. The myosin inhibitor mavacamten reverses the increased contractility caused by HCM thick filament mutations, and we ...
Redwood, Charles, Sparrow, Alexander J, Robinson, Paul, Daniels, Matthew J, Watkins, Hugh   +4 more
core   +1 more source

Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Clopidogrel is an antiplatelet agent widely utilized in cardiology. It is a prodrug activated in the liver by the cytochrome P450 isoform CYP2C19. Variability in the CYPC2C19 gene influences the activation and efficacy of clopidogrel. This is covered in guidelines from the Clinical Pharmacogenetics Implementation Consortium, the Dutch ...
Cinzia Dello Russo, Luigi Venetucci, Abisope Akintola, Dimitri Gagliardi, Ronnie Ramlogan, Munir Pirmohamed   +5 more
wiley   +1 more source

Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration

CPT: Pharmacometrics & Systems Pharmacology
Mavacamten is a selective, allosteric, reversible cardiac myosin inhibitor that has been developed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Peter Chang, Vidya Perera, David H. Salinger, Samira Merali, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amy J. Sehnert, Maria Palmisano, Amit Roy   +10 more
doaj   +1 more source

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy

British Journal of Pharmacology, Volume 183, Issue 5, Page 1122-1139, March 2026.
Abstract Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood.
Elisa Kiselev, Wilson Agyapong, Bjarne Jürgens, Elisa Mohr, Shambhabi Chatterjee, Hannah J. Hunkler, Jawad Salman, Giuseppe Cipriano, Marco Bentele, Junqing Liu, Jonas Specht, Kaja S. Menge, Florian J. G. Waleczek, Jonas A. Haas, Anselm A. Derda, Kristina Sonnenschein, Anika Gietz, Susanne Neumüller, Angelika Pfanne, Oliver Beetz, Michael Pflaum, Bettina Wiegmann, Yiangos Psaras, Christopher Toepfer, Robert Zweigerdt, Ante Radocaj, Theresia Kraft, Andre Zeug, Evgeni Ponimaskin, Wilhelm Korte, Alexander Horke, Arjang Ruhparwar, Maximilian Fuchs, Ke Xiao, Christian Bär, Natalie Weber, Thomas Thum   +36 more
wiley   +1 more source

One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy

Frontiers in Cardiovascular Medicine
Mavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM).
Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Emily L. Chu, Emily E. Keamy-Minor, Ishan Dhananjay Paranjpe, Wilson L. Tang, Jack W. O’Sullivan, Jack W. O’Sullivan, Jack W. O’Sullivan, Yaanik B. Desai, Yaanik B. Desai, Michael B. Liu, Michael B. Liu, Elise Munsey, Kimberly Hecker, Isabella Cuenco, Beth Kao, Ellen Bacolor, Colleen Bonnett, Andrea Linder, Kathleen Lacar, Nancy Robles, Cindy Lamendola, Allysonne Smith, Joshua W. Knowles, Joshua W. Knowles, Joshua W. Knowles, Joshua W. Knowles, Marco V. Perez, Marco V. Perez, Marco V. Perez, Marco V. Perez, Masataka Kawana, Masataka Kawana, Masataka Kawana, Karim I. Sallam, Karim I. Sallam, Karim I. Sallam, Chad S. Weldy, Chad S. Weldy, Chad S. Weldy, Matthew T. Wheeler, Matthew T. Wheeler, Matthew T. Wheeler, Matthew T. Wheeler, Victoria N. Parikh, Victoria N. Parikh, Victoria N. Parikh, Victoria N. Parikh, Heidi Salisbury, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, the Stanford Center for Inherited Cardiovascular Disease, Karim I Sallam, Masataka Kawana, Chad S Weldy, Marco Perez, Joshua W Knowles, Jason Tso, Cindy Lamendola, Allysonne Smith, Nancy Robles, Colleen Bonnett, Ellen Bacolor, Kimberly Hecker, Isabella Cuenco, Beth Kao, Elise Munsey, Andrea Linder, Kathleen Lacar, Julia Platt, Chloe Reuter, Tia Moscarello, Ryan Murtha, Jennifer Kohler, Hannah Ison, Mitchel Pariani, Anusha Klinder, Priya Nair, Jennifer Marino, Andrea Linder, Ruchi Patel, Matthew T Wheeler, Euan A Ashley, Victoria N Parikh   +92 more
doaj   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Clinical Evaluation of Drug–Drug Interactions With Aficamten

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive drug–drug interaction (DDI) evaluation of aficamten was achieved through two phase 1 studies in ...
Neha Maharao, Donghong Xu, Punag Divanji, Tyrell J. Simkins, Jianlin Li, Camelia Dumitrescu, Priyanka Solanki, Adrienne Griffith, Stephen B. Heitner, Stuart Kupfer, Polina German, Justin D. Lutz   +11 more
wiley   +1 more source

Biomechanical response of ultrathin slices of hypertrophic cardiomyopathy tissue to myosin modulator mavacamten [PDF]

Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial disorder of the heart, but effective treatment options remain limited. Mavacamten, a direct myosin modulator, has been presented as novel pharmacological therapy for HCM.
de Groot, Natasja M.S., Amesz, Jorik H., Langmuur, Sanne J.J.; id_orcid, Zhang, Lu, Taverne, Yannick J.H.J., de Jong, Peter L., Schinkel, Arend F.L., Manintveld, Olivier C.   +7 more
core   +1 more source